Technical Information

BACKGROUND INFORMATION

OphthalmoMed proudly supplies intravitreal injection packs for around 50% of the cost of those that are commonly available on the Australian and NZ market. Previously, these kits cost $23.50 wholesale for businesses in Australia. We now provide the same full contents, high quality, sterile TGA approved packs for only $12.00 AUL each (for customers requiring 1,000+ packs/annum).

 

The cost for clinics and hospitals was too high, with leading pack types available in the market costing $23.

 

OphthalmoMed directors spent a year investigating a number of manufacturers overseas, finally deciding on a large scale and hi-tech manufacturer with full ISO 9000 certification and European Conformity Assessment Certification required for TGA Approval.

 

We trialled the packs with several of our ophthalmologists' clients who confirmed that they were high quality, had complete contents required for an intravitreal procedure and would like to use them in their Practices.

Therapeutic Goods Administration (TGA) sponsorship by ophthalmoMed Pty Ltd and necessary TGA registration as a Medical Device Class IIa was obtained.

 

We launched ophthalmoMed as a business dedicated to cutting intravitreal packs costs significantly for our ophthalmology clients and remain dedicated to that focus.

 

From what was an initial idea to just supply our local ophthalmology practices with affordable intravitreal packs, has organically expanded without website or advertising (until September 2021) so we now are shipping 20,000 unit consignments and distributing the packs across all the main Australian centres and New Zealand. 

 

We are happy to provide samples at n/charge for your ophthalmology department to trial.

Please feel free to contact me with any questions, as we look forward to achieving positive clinical results and significant cost savings for your ophthalmology service.

INTRAVENOUS PACK USE

The disposable intravitreal packs contain all disposable instruments & consumables necessary for vitreoretinal injection for the treatment of Age-Related Macular Degeneration and other conditions. Intravitreal injection is performed in the posterior segment of the eye through the pars plana and is used to inject substances that act upon the retina. The introduction of Anti-VEGF medications has led to an increase in the use of intravitreal injections and they have become the standard treatment of Age-Related Macular Degeneration. Ant-VEGF drugs have also been approved as treatments for Diabetic Retinopathy and Retinal Vein Occlusion.’